AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BMY · NYSE · Drug Manufacturers - General

Bristol-Myers Squibb (BMY)

Develops medicines for cancer, blood disorders, immunology, cardiovascular disease and neuroscience.

$62.37

vs last close−0.25 (−0.41%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	10,966	11,477	11,865	12,201	11,892	12,342	11,201	12,269	12,222	12,503	11,489	12,973
Cost of revenue	4,746	4,985	5,275	5,400	5,275	4,918	3,033	3,372	3,435	4,097	3,421	3,726
Gross profit	6,220	6,492	6,590	6,801	6,617	7,424	8,168	8,897	8,787	8,406	8,068	9,247
	4,116	4,540	5,055	4,217	4,329	4,893	4,671	5,123	5,148	5,593	4,703	5,161
Research & development	2,178	2,476	2,694	2,295	2,353	2,788	2,257	2,580	2,528	2,586	2,649	2,959
	1,938	2,064	2,361	1,922	1,976	1,852	1,584	1,713	1,789	2,181	1,617	1,826
Selling & marketing	0	1,400	2,367	0	1,983	1,500	1,584	0	0	0	0	0
General & administrative	0	664	0	0	0	352	0	0	0	0	0	0
Other expenses	0	0	0	0	0	253	830	830	831	826	437	376
Operating income	2,104	1,952	1,535	2,584	2,288	2,531	3,497	3,774	3,639	2,813	3,365	4,086
	33	−278	−13,051	−1,298	−612	−2,356	−526	−2,001	−525	−1,343	−125	0
Interest expense	280	316	425	521	505	496	494	485	480	432	411	407
Other non-operating income	−295	−38	12,626	777	107	1,860	32	1,516	45	911	−286	−407
Income before tax	2,137	1,674	−11,516	1,286	1,676	175	2,971	1,773	3,114	1,470	3,240	4,086
Income tax expense	203	−88	392	−398	461	99	509	460	919	384	561	770
Net income from continuing operations	1,934	1,762	−11,908	1,684	1,215	76	2,462	1,313	2,195	1,086	2,678	3,316
Other adjustments	0	0	0	0	−4	0	0	−1	0	0	0	0
Net income	1,928	1,762	−11,911	1,680	1,211	72	2,456	1,310	2,201	1,087	2,677	3,317
EPS, basic	$0.94	$0.87	−$5.89	$0.83	$0.60	$0.04	$1.21	$0.64	$1.08	$0.53	$1.31	$1.62
EPS, diluted	$0.93	$0.87	−$5.89	$0.83	$0.60	$0.04	$1.20	$0.64	$1.08	$0.53	$1.31	$1.62
Weighted average shares, basic	2,057	2,027	2,023	2,027	2,028	2,029	2,031	2,035	2,038	2,041	2,044	2,042
Weighted average shares, diluted	2,064	2,033	2,023	2,029	2,031	2,037	2,037	2,038	2,038	2,041	2,044	2,048
EBITDA	4,852	4,454	−8,559	4,403	4,773	2,551	4,477	3,269	4,605	2,879	4,245	4,940
Depreciation & amortization	2,435	2,464	2,532	2,596	2,592	1,880	1,012	1,011	1,011	977	594	450
EBIT	2,399	1,990	−11,091	1,807	2,181	671	3,465	2,258	3,594	1,902	3,651	4,493